NEW YORK, Oct. 29 /PRNewswire-FirstCall/ -- Xenomics, Inc., (Pink Sheets: XNOM; FWB:X37) announces that it has granted Asuragen, Inc. co-exclusive worldwide rights to incorporate NPM1 technology into Asuragen’s molecular diagnostic products. Under the terms of this agreement, Asuragen will have the right to develop, manufacture and market products for the diagnosis, stratification and monitoring of patients with Acute Myeloid Leukemia (AML).
